---
schema_version: "secwatch.filing_event.v1"
accession: "0001517022-25-000045"
form_type: "8-K"
ticker: "AKBA"
cik: "0001517022"
company_name: "Akebia Therapeutics, Inc."
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:21:18.994062+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Akebia Q3 net income $0.5M; Vafseo revenue $14.3M; DaVita pilot ongoing

## Summary
- Q3 total revenue $58.8M (up 57% YoY vs $37.4M); net income $0.5M vs net loss $20.0M in Q3 2024.
- Vafseo net product revenue $14.3M (launched Jan 2025); Auryxia net revenue $42.5M (up from $35.6M).
- DaVita operational pilot started Aug 18 over 100 clinics, expected to complete in Q4; target 275K patient access by year-end.
- FDA Type C meeting: no alignment on Phase 3 for non-dialysis; Akebia will not pursue broad label for non-dialysis.
- Cash $166.4M; company believes financed to achieve profitability under current operating plan.

## SEC filing metadata
- accession: 0001517022-25-000045
- form_type: 8-K
- ticker: AKBA
- cik: 0001517022
- company_name: Akebia Therapeutics, Inc.
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517022/000151702225000045/0001517022-25-000045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517022/000151702225000045/akba-20251110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001517022-25-000045
- JSON: https://secwatch.observer/filing/0001517022-25-000045.json
- Plain text: https://secwatch.observer/filing/0001517022-25-000045.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.